Ottawa, Canada May 1, 2018 – Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that Jason Burke has been appointed Chief Financial Officer effective immediately.
Mr. Burke has more than 20 years of financial leadership experience across a broad range of industries overseeing the finance function for high-growth companies. Prior to joining Orion, he served as Chief Operating Officer and Chief Financial Officer (CFO) of Conversant Intellectual Property Management where he oversaw a $560M leveraged take private transaction by Sterling Partners out of Chicago. He also served as CAO of Massachusetts-based AVID Technologies, a publicly traded firm with $680M in annual revenues and 2,500 employees worldwide. Before moving to Massachusetts, Mr. Burke served as CFO of the Business Analytics division of IBM (Formerly Cognos) where he oversaw major portions of IBM’s $5 Billion acquisition of Cognos in 2008. Mr. Burke started his career with Deloitte & Touche LLP, where he was Manager in the Assurance and Advisory Services Group. Mr. Burke is a CPA and earned a Bachelor of Business Administration/Accounting from St. Francis Xavier University in Nova Scotia. As a result of his achievements, Mr. Burke was recognized by Treasury and Risk Magazine as one of the Global Top 40 under 40 finance professionals in 2010.
As CFO at Orion Biotechnology Canada, Mr. Burke will be working closely with the senior management team and the Board of Directors overseeing the finance organization, providing strong financial governance and risk management, and ensuring that the company is well positioned for growth and driving shareholder value.
“It is a tremendous opportunity to join the Orion executive team at such an exciting time” said Mr. Burke. “The company has a tremendous portfolio of product candidates which have the potential to address significant areas of unmet need. I am thrilled to play a role in the development of the company’s portfolio of product candidates and position the company for long-term operational and financial success.”
“The Board of Directors and I are delighted to welcome Jason to our executive leadership team as our new CFO at this important juncture in the development of our Company” said Mark Groper President and CEO. “Jason brings considerable financial acumen and experience, as well as numerous relationships within the investment community, which will be important assets as we move forward with our growth plans. With Jason at the finance helm, I’m confident we’ll be well positioned to meet our goals.”
About Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd, is a privately held pharmaceutical company founded on the vision of radically improving the health of the global population through successful treatment and prevention of the most serious chronic illnesses and life-threatening diseases. Since 2011, Orion has been developing a robust pipeline of potential products based on novel formulations discovered in different parts of the world. Our close ties to diverse institutions and experts around the globe continue to stimulate the rapid discovery of promising new treatments. With operations in North America, Europe and Asia, Orion brings together innovative technologies from some of the world’s leading research institutions such as the Mintaka Research Foundation and the Center for Public Health Research at Nanjing University. Learn more at www.orionbiotechnology.com.
This press release contains forward-looking information, which reflects Orion’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Orion’s control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Orion assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.